Propoxyphene (Darvon®) Addiction and Withdrawal Syndrome

  1. ROBERT C. WOLFE, M.D.;
  2. MARCUS REIDENBERG, M.D., F.A.C.P.; and
  3. RAUL H. VISPO, M.D.
  1. Philadelphia, Pennsylvania
  1. Requests for reprints should be addressed to Robert C. Wolfe, M.D.,
    Suite 106, The Cambridge, Philadelphia, Pa. 19144

SUMMARY

A 31-year-old woman with longstanding psychiatric difficulty was introduced to propoxyphene (Darvon®) by prescription after gynecologic surgery. She gradually developed a primary addiction and took an oral dose that at times reached 2,300 mg daily. She was hospitalized for drug withdrawal and initially maintained on 1,300 mg propoxyphene daily. Laboratory evaluation showed no evidence of chronic liver, kidney, or hematologic toxicity. Placebos were then substituted for the propoxyphene, and definite abstinence symptoms and signs occurred. These consisted of anorexia, rhinitis, and fatigue, followed by irritability and insomnia. Vomiting developed by the end of 48 hr of abstinence. Propoxyphene was then reinstituted, and within 24 hr the patient was asymptomatic. We conclude that tolerance and physical dependence to propoxyphene can occur.

Article and Author Information

  • From the Temple University Medical Center and the Institute for Alcoholism and Narcotic Addiction, Philadelphia, Pa.

  • This study was supported in part by research grant FR00349, U. S. Public Health Service, Washington, D. C.

    • Received November 18, 1968.
    • Accepted January 7, 1969.
« Previous | Next Article »Table of Contents